The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

<p>Abstract</p> <p>Background</p> <p>Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increasing the progression-free survival (PFS) time by pirfeni...

Full description

Bibliographic Details
Main Authors: Nakata Koichiro, Takahashi Hiroki, Suga Moritaka, Taguchi Yoshio, Ogura Takashi, Azuma Arata, Ebina Masahito, Kondoh Yasuhiro, Taniguchi Hiroyuki, Sato Atsuhiko, Sugiyama Yukihiko, Kudoh Shoji, Nukiwa Toshihiro
Format: Article
Language:English
Published: BMC 2011-07-01
Series:Respiratory Research
Online Access:http://respiratory-research.com/content/12/1/93

Internet

http://respiratory-research.com/content/12/1/93

Similar Items